Streetbeat News

Outset Medical, Inc.

https://www.outsetmedical.com

Industry

Medical - Devices

Outset Medical, Inc., a medical technology company, develops a hemodialysis system for dialysis. It provides the Tablo Hemodialysis System, which comprises a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings. The company was formerly known as Home Dialysis Plus, Ltd. and changed its name to Outset Medical, Inc. in January 2015. Outset Medical, Inc. was incorporated in 2003 and is headquartered in San Jose, California.

Open

0.79

Mkt cap

40M

Volume

1.5M

High

0.90

P/E Ratio

-0.28

52-wk high

6.37

Low

0.77

Div yield

N/A

52-wk low

0.43

Outset Medical Inc received a notice from Nasdaq on September 23 for failing to satisfy a continued listing rule or standard.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2024 | 8:12 pm

RBC Capital has downgraded Outset Medical (NASDAQ:OM) from Outperform to Sector Perform and lowered its price target from $6 to $3.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 7:39 pm

U.S. stocks traded higher with significant gains in the Nasdaq Composite, Dow, and S&P 500. US Foods Holding Corp. reported better-than-expected sales, while XPEL, Viasat, and GSE Systems saw substantial stock price increases. Conversely, Cardlytics, Outset Medical, and Bumble experienced significant declines due to poor financial results.

Portfolio Pulse from Avi Kapoor

August 08, 2024 | 6:49 pm

TD Cowen analyst Joshua Jennings maintains a Buy rating on Outset Medical (NASDAQ:OM) but lowers the price target from $9 to $3.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 6:09 pm

U.S. stocks surged with the Dow Jones gaining over 500 points. Eli Lilly reported strong Q2 earnings and raised its full-year guidance. XPEL, Viasat, and GSE Systems saw significant stock price increases due to positive earnings and acquisition news, while Cardlytics, Outset Medical, and Bumble experienced sharp declines following disappointing earnings.

Portfolio Pulse from Avi Kapoor

August 08, 2024 | 4:06 pm

Outset Medical shares are trading lower after the company reported worse-than-expected Q2 financial results and cut its FY24 revenue guidance.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 11:39 am

Digital Turbine (APPS) shares surged over 20% in pre-market trading after reporting better-than-expected quarterly results. Other notable pre-market movers include Expion360 (XPON), Anew Medical (WENA), Luxurban Hotels (LUXH), Coeptis Therapeutics (COEP), Aspen Aerogels (ASPN), Sezzle (SEZL), Color Star Technology (ADD), Fluence Energy (FLNC), and Staffing 360 Solutions (STAF) among gainers. Losers include Cardlytics (CDLX), Outset Medical (OM), Bumble (BMBL), Viracta Therapeutics (VIRX), Greenlane Holdings (GNLN), JFrog (FROG), Know Labs (KNW), Dutch Bros (BROS), Fastly (FSLY), and Precigen (PGEN).

Portfolio Pulse from Avi Kapoor

August 08, 2024 | 10:02 am

Eli Lilly, US Foods, Blue Bird, Outset Medical, and Parker-Hannifin are stocks to watch today. Eli Lilly and US Foods are expected to report earnings, Blue Bird reported strong Q3 results and a new CEO, Outset Medical reported poor Q2 results and cut FY24 guidance, and Parker-Hannifin is also expected to report earnings.

Portfolio Pulse from Avi Kapoor

August 08, 2024 | 6:26 am

Outset Medical shares are trading lower after the company reported worse-than-expected Q2 financial results and cut its FY24 revenue guidance.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 8:22 pm

Outset Medical has lowered its FY24 revenue guidance from $145M-$153M to approximately $110M, which is below the estimated $146.41M. The company also expects its non-GAAP gross margin to be in the low-to-mid 30% range.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 8:18 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.